Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 30;13:3601–3617. doi: 10.2147/CMAR.S300861

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

SDC2 promoter methylation level in subgroups of patients with CRC, stratified based on gender, age and other criteria (UALCAN). (A) Boxplot showing relative promoter methylation level of SDC2 in normal and CRC samples. (B) Boxplot showing relative promoter methylation level of SDC2 in normal individuals of either gender or male or female CRC patients. (C) Boxplot showing relative promoter methylation level of SDC2 in normal individuals of any age or in CRC patients aged 21–40, 41–60, 61–80, or 81–100 yr. (D) Boxplot showing relative promoter methylation level of SDC2 in normal individuals of either race or in CRC patients of Caucasian, African-American or Asian. (E) Boxplot showing relative promoter methylation level of SDC2 in normal individuals of either weight or in CRC patients with normal weight, extreme weight, obese or overweight. (F) Boxplot showing relative promoter methylation level of SDC2 in normal individuals or in CRC patients in stages 1, 2, 3 or 4 tumors. (G) Boxplot showing relative promoter level of SDC2 in normal individuals of either histology or adenocarcinoma or mucinous adenocarcinoma CRC patients. (H) Boxplot showing relative promoter methylation level of SDC2 in normal individuals of any nodal metastasis status or in CRC patients in N0, N1, N2. ***p< 0.001.